Horst Kieserling is considered a pioneer of microcurrent therapy in Germany. After sixteen years in the service of the pharmaceutical company Hoechst, Horst Kieserling, trusting in God, decided to found a company in the beautiful nature of the Oberallgäu in 1995.
Credo: Away from the leaflets and towards naturopathy with therapies that are well tolerated by patients and yet have a convincing effect! In the first few years he was only accompanied by Via Nova natural products, then came the fateful encounter with an importer of American microcurrent devices. He received his first training in local and meridian therapy from him in Vienna. After the medical approval of the MSG 1200 developed in Bochum, many further training courses followed, e.g. B. in reflex muscle therapy and targeted frequency selection.
The MSG 1200 underwent continuous improvements and was offered by Horst Kieserling under various brand names: Beauty-Master 1999, Clinic-Master 2000, Magic-Power-Master 2005, Regu-Cell 2009. This was followed by the patient version Travel-Home in 2010.
His idea of combining microcurrent devices with alkaline wraps was groundbreaking. The modern ReguCellTouch was available, with which Horst Kieserling was able to realize all of his long-cherished dreams at the highest technical level. The outstanding technical and therapeutic features were developed by the proven company Dr. Schwab GfT developed.
The invention of JERICO, as an additional influence on the tissues, has triggered a quantum leap in patient satisfaction.
In the future, patient-friendly therapies, individual customer care and exemplary support for every practice should lead to the enthusiasm of more and more new users at home and abroad.
Important NOTE: The modes of action and medical applications described below for the devices from “ReguCell Products” come from complementary medicine and are intended as an alternative and supplement to scientifically based treatment methods in conventional medicine. The statements are currently only based on studies of small cohort groups, pilot studies, application observations and/or experience reports. In particular, there are no studies of evidence level Ib (methodologically high-quality randomized placebo-controlled studies with a sufficient number of test subjects) or even level Ia (meta-analysis based on several methodologically high-quality level Ib studies), so that the therapy, methodology and the options for action described have not yet been sufficiently proven by conventional medical science and are therefore considered controversial.
